Description

KX-826 (Pyrilutamide) Powder

 

 

 

CAS Number	1272719-00-2
Other Names	Pyrilutamide, SCHEMBL1444126, EX-A5504, MS-28963, HY-145451, CS-0374724
IUPAC Name	4-[3-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
Molecular Formula	C₂₁H₁₅F₅N₄O₂S
Molecular Weight	482.43
Purity	≥99% Pure (LC-MS)
Liquid Availability	30mL Plant-Based liquid (5mg/mL, 150mg bottle)
Powder Availability	500 milligrams
Gel Availability	N/A
Storage	Store in cool dry environment, away from direct sunlight.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

What is KX-826?

KX-826, also referred to as pyrilutamide, is an androgen receptor antagonist, commonly categorized as a nootropic, that assists in treating androgenic alopecia (AGA). Kintor Pharma is the main manufacturer of KX-826. The company is currently in phase II trials; each trial is randomized, double-blind, and placebo-controlled in order to ensure the compound meets all efficacy and safety standards set in place.

AGA tends to occur due to the sensitivity of the hair follicles and how they react to dihydrotestosterone (DHT). While DHT typically promotes the development of male sex characteristics, too much circulating DHT can have negative side effects such as acne, inflammatory lesions, and AGA. Popular treatments currently on the market include finasteride and dutasteride, both of which are considered 5ɑ reductase inhibitors. Through the inhibition of 5ɑ reductase, DHT production is reduced which assists in decreasing the number of androgenic diseases. Another popular treatment more similar to KX-826 is CB-03-01, or Clascoterone. Clascoterone works as an androgen receptor antagonist in the sebaceous glands and hair follicles, leading to a decrease in DHT. KX-826 works in a similar manner and is considered the fastest growing androgen receptor antagonist, second only to CB-03-01 (https://en.kintor.com.cn/news/81.html).

Results of KX-826 Treatment

Many of the current studies regarding the usage of KX-826 focus on both the safety and efficacy of the compound. A popular study conducted by Jianzhong et. Al was presented to Kintor Pharma regarding the effective use and dosages of KX-826 for hair growth while in phase II clinical trials. The study utilized 120 animal test subjects and assigned each subject to receive a dosage of 2.5 mg twice per day, 5 mg once per day, 5 mg twice per day, or a placebo group.

Results were based on the target area hair count (TAHC) after a 24 week experimental period. Overall, the study found that the most advantageous dose for maximum hair growth was 5 mg of KX-826 twice daily. This administration led to a 22.73 hairs per square cm increase above baseline TAHC and a 15.34 hairs per square cm increase above the TAHC of the placebo group. Based on the important dosage information gathered in this study, the compound is able to begin transitioning into the next phase of trials (https://folliclethought.com/kintor-pharmaceutical-kx-826-phase-2-results-with-poster/).

Further Research

 

Phase III of the KX-826 trials were very similar to the phase II trials. There were 416 subjects examined over a 24 week treatment period, and results were based on the change from baseline TAHC. While there has been little information given regarding the dosages researchers are testing for phase III, the initial results are promising and indicate further advancement in the clinical trial phases. Phase III involves a larger number of test subjects than the two previous trials. This allows researchers to gather their data from a larger experimental group, ultimately leading to more accurate data regarding efficacy and safety.

KX-826 is being compared to Dutasteride and Clascoterone, both of which are very popular hair loss treatments on the market, briefly mentioned above. Researchers have frequently remarked that the results of these compounds are incredibly similar, despite having different physiological proceedings. As Dutasteride and Clascoterone are already established and studied forms of treatment, there is great promise that KX-826 is well on its way to become a widely-developed solution for androgenic alopecia.

In addition to their research regarding KX-826, Kintor Pharma has begun clinical trials on another hair loss drug, GT20029. This compound is considered an androgen receptor degrader, while KX-826 is an androgen receptor antagonist. AR degraders interact with the receptors and cause degradation to the structural integrity through use of the E3 ubiquitin ligase pathway. This leads to a decrease in androgen production.

Overall, the results of these various studies show that there are many promising new treatments for hair loss. The research that Kintor Pharma has been doing in collaboration with other pharmaceutical companies, emphasizes the efficacy of compounds such as KX-826, GT20029, and CB-03-01. Since the clinical trials have already produced successful results, the researchers spearheading the projects are hopeful in their efforts to advance their studies surrounding the AR antagonists (https://www.hairlosscure2020.com/category/pyrilutamide/).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

KX-826 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

 

 

 

File Name	View/Download
11-02-2022-Umbrella-Labs-KX-826-Pyrilutamide-Certificate-of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)

 

 

Additional information

Options	30mL Plant-Based Liquid 5mg/mL 150mg bottle, 500 Milligrams Powder